Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tamoxifen Dose Adjustment in ER+ Breast Cancer
NCT04312347Completed
- Sponsor
- Nalagenetics
- Start
- Sep 2019
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of tamoxifen in breast cancer, sponsored by Nalagenetics. Primary endpoints: Effects of genotype and phenotype of CYP2D6 on plasma and serum concentration of tamoxifen and its metabolites, Effects of dose recommendation of tamoxifen based on CYP2D6 genotyping results on endoxifen levels and 1 more. Started Sep 2019; status: completed.
02
Drugs
tamoxifen
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04312347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04312347.